Sign up
Pharma Capital

LexaGene moves forward with its faster, easier pathogen detection

LexaGene Holdings (CVE:LXG) (OTCQB:LXXGF) Co-founder and CEO Dr. Jack Regan joined Katie Lewis from the Vancouver studio of Proactive Investors to discuss the firm's recent announcement.

LexaGene's key feature is the open access nature of the instrument that allows end users to customize the instrument to target any pathogen of interest. The process is as simple as collecting a sample, loading it into the instrument using a preparation cartridge and pressing “go.” The instrument is able to process multiple samples at a time, returning results within around one hour.forward with its faster, easier pathogen detection

 

View full LXG profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.